Gene Editing TechnologyPrecision is on track to hit multiple milestones to validate their ARCUS genome editing technology.
Preclinical DataPBGENE-HBV treatment demonstrated significant efficacy in preclinical studies, including up to 99% elimination of covalently closed circular DNA (cccDNA) in non-human primates.
Regulatory ProgressFast Track designation from the FDA for ECUR-506, an in vivo gene insertion therapy designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency.